For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET
Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions
Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.
Read
Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET
New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check
As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.
Read
Commented by Fabian Lorenz on November 23rd, 2022 | 11:43 CET
China causes a bang in Qatar: Opportunity for Nel ASA, Plug Power, First Hydrogen, ITM Power
Germany wanted to secure liquefied natural gas (LNG) from Qatar to reduce its dependence on Russia. But now China is digging in and securing LNG supplies from the emirate for the next 27 years. During this time, 108 million tons are to be supplied. Germany only wanted to commit for 5 years. While this does not necessarily take the German government's deal off the table, it does show that gas supplies will continue to be anything but secure or cheap in the future. And it shows how vital hydrogen will be in the future and that policymakers must push for its promotion because hydrogen from renewable energies can at least partially replace natural gas. Companies like Nel ASA, Plug Power and First Hydrogen can benefit from this. In 2022, however, only First Hydrogen was convincing.
Read
Commented by Fabian Lorenz on November 18th, 2022 | 10:15 CET
Shares of Nordex, BYD, and Almonty Industries: Winners of the energy transition
The energy turnaround is becoming unbearable. But it will take time for the world to switch to renewable energies in private and public life. Today, we take a look at three winning stocks. Among them is BYD. The Chinese carmaker has switched to hybrid and all-electric vehicles and is on track to take Tesla's place as the leading electric carmaker. The first three models for Germany have now been confirmed. At Nordex, sentiment is improving. The share price has jumped, and a large order gives hope. However, wind turbines and batteries cannot be manufactured without raw materials such as tungsten. Now a German research house has taken a closer look at Almonty Industries. The share is on the verge of a revaluation and has a price potential of 100%.
Read
Commented by Fabian Lorenz on November 17th, 2022 | 10:40 CET
Breaking news drives Nel ASA share: What are BioNTech and Kleos Space up to?
Growth stocks are currently celebrating a comeback. In particular, when there is also positive news from the company itself, as is the case with Nel ASA. The share of the hydrogen specialist increased by 40% within 4 weeks, and analysts see further potential for their "Top Pick". And then the Norwegians announced a cooperation with General Motors yesterday. BioNTech is also looking good from a chart and operational point of view. The cash box is full, allowing the Mainz-based company to increase production capacities. There is also something happening with space stocks. The valuation of Elon Musk's SpaceX is said to have risen by USD 25 billion in the latest round of financing, which should also improve the environment for Kleos Space. The specialist in space-based high-frequency reconnaissance is facing important weeks.
Read
Commented by Fabian Lorenz on November 10th, 2022 | 12:26 CET
Plug Power after the horror numbers, and what are Varta and Altech Advanced Materials doing?
Climate change, high gas and oil prices and the dependence on "difficult" energy suppliers: There are many reasons why hydrogen and electromobility are among the undisputed topics of the future. Accordingly, shares from these sectors are popular with investors. Plug Power is one of the favorites. The Americans have disappointed (again) with their latest quarterly figures, but the share price is still rising, and analysts are also positive. Battery specialist Altech Advanced Materials is also currently doing well. The cooperation with Fraunhofer in the field of solid-state batteries is taking shape. Varta, on the other hand, is currently working on bottoming out, but analysts advise selling.
Read
Commented by Fabian Lorenz on November 9th, 2022 | 13:31 CET
BioNTech, Porsche and Pathfinder Ventures - Looking good
BioNTech's figures were convincing, and the chart looks good again. Porsche is doing well. Not all analysts see further price potential and the price targets diverge. However, a promotion to the DAX beckons. Pathfinder Ventures is also benefiting from surprisingly high demand. The winter camping resort offers are practically sold out. But first to BioNTech. After competitor Moderna had disappointed last week, the quarterly figures of the Mainz-based biotech Company were convincing. And due to the full pipeline, investors can expect a lively news flow in the coming year. Analysts are bullish.
Read
Commented by Fabian Lorenz on November 3rd, 2022 | 12:01 CET
BioNTech, Moderna and Defence Therapeutics right in the middle of the billion-dollar mRNA market! And Bayer?
BioNTech and Moderna's mRNA-based vaccines have successfully contributed to the containment of the COVID-19 pandemic. This has helped the relatively new technology for developing vaccines and other drugs to make a breakthrough. According to Precedence Research market researchers, the mRNA therapeutics market is expected to exceed USD 128 billion by 2030. The average annual growth would be around 13%. German top dog BioNTech is betting heavily on vaccines to fight cancer, among other things. Defence Therapeutics is now also entering the billion-dollar market, continuing the positive newsflow of recent weeks. The Canadians are opening up their platform for mRNA research, and their valuation is anything but expensive. Bayer is also too cheap at the moment. Analysts at least see a good 50% price potential.
Read
Commented by Fabian Lorenz on November 2nd, 2022 | 12:34 CET
Gas price collapses: BASF, Porsche, Meta Materials in an upward trend
The sharp fall in gas prices is creating a good mood among investors. This week, the forward contract (TTF) for natural gas fell to below EUR 100 per MWh, its lowest level since June. This is fueling hopes that inflation will cool and the recession will be less severe. The direct beneficiary is, of course, BASF. In addition, a subsidiary is currently earning billions, and analysts see further price potential overall. According to them, the chemical group is currently "simply too cheap". This could also be the case with hot stock Meta Materials. Recently, new orders have given a boost to the share price. Should the Canadians continue the commercialization of the patent portfolio so successfully, significantly higher prices are possible. After the stuttering IPO, the Porsche share has stepped on the gas. But from the analysts' point of view, the air is slowly getting thinner.
Read
Commented by Fabian Lorenz on October 28th, 2022 | 12:54 CEST
BioNTech, Nel ASA and Desert Gold - Ripe for uptrend?
The profit warning at ITM Power sent shockwaves throughout the hydrogen sector. Does this mean that the friendly development of the Nel share of the past few days has already ended? Analysts see little potential, at least at present, but are optimistic for the long term. Goldman Sachs is also optimistic about the gold price. At least the chances for a rise to over USD 2,000 are better than for a renewed decline. Producers like Barrick Gold should profit from this, and explorers like Desert Gold even disproportionately. At BioNTech, there is currently no impetus for an upward trend, and analysts' price targets diverge considerably. However, rumors from the US are encouraging.
Read